From October 25 to 27, 2024, the Élysée Palace was transformed into an exhibition space dedicated to promoting French manufacturing and opened its doors to the general public. Companies, associations, producers, and industrial players committed to the Made in France label, such as UPSA, were honored during this event.
UPSA Exhibited at the Élysée Palace
UPSA at the Élysée
Among over 2,200 applications, our flagship paracetamol-based medicine (Dafalgan 1G) was awarded a prize at the Grand Made in France Exhibition.
We proudly represented the Lot-et-Garonne region in Paris, showcasing French excellence
A Presidential Speech Honoring UPSA
During his opening speech, the President of the Republic, Emmanuel Macron, highlighted UPSA as an example of French expertise and the efforts made in terms of national sovereignty.
This recognition underscores the importance of UPSA’s commitments.
Watch the speech at 4:27.
Spotlight on UPSA Paracetamol
UPSA represented the French savoir-faire of the Lot-et-Garonne region at the Grand Made in France Exhibition.
Each year, UPSA, the leading manufacturer of paracetamol-based medicines in France, produces over 300 million boxes at its Agen site. Our laboratory adapts production according to health demands and ensures continuous access to essential medicines for the French population and patients in the 60 countries to which we export.
A Conference on the Appeal of Made In France
Laure Lechertier, Director of Public Affairs, Market Access, Communication, and CSR at UPSA, participated in a conference focused on the attractiveness of the Made in France label.
For UPSA, a committed player in relocating the active ingredient production of paracetamol to France, producing 100% in France is not only a strategic choice to secure the paracetamol supply chain and support the country’s health sovereignty, but also to reduce our environmental footprint. This approach strengthens our image both in France and internationally, where Made in France is a mark of quality and reliability.
